JLPC(SH:600513) Zheng Quan Zhi Xing·2025-08-26 16:35Core Viewpoint - The company has developed a "Quality Improvement and Efficiency Enhancement" action plan for 2025, focusing on enhancing shareholder returns and aligning with national economic policies [1][2]. Group 1: Business Focus and Performance - The company operates as a national high-tech enterprise, integrating research, production, and sales in the pharmaceutical sector, with a diverse product range including specialty APIs, chemical drug formulations, biological drugs, and medical devices [1]. - The company reported a revenue of 1,285.34 million yuan, representing a year-on-year growth of 14.12%, with a net profit attributable to shareholders of 19.51 million yuan after deducting non-recurring gains and losses [2]. Group 2: Dividend Policy and Shareholder Returns - The company emphasizes sharing development results with shareholders and has optimized its profit distribution policy, proposing a cash dividend of 0.089 yuan per share, amounting to a total dividend payout ratio of 30.19% [2][3]. Group 3: Innovation and Core Competitiveness - Innovation is central to the company's strategy, with increased R&D investment and a focus on building a diversified innovation system, resulting in the approval of 8 production batches and 11 invention patents this year [3][4]. Group 4: Investor Communication and Value Transmission - The company prioritizes investor relations, conducting 5 investor communication activities in 2025 to enhance transparency and trust, while actively addressing investor concerns [5]. Group 5: Corporate Governance and Operations - The company adheres to legal regulations and continuously improves its governance structure, ensuring effective supervision and decision-making processes [6]. Group 6: Talent Development and Organizational Vitality - The company places significant importance on talent development, implementing various training programs and performance evaluation mechanisms to enhance employee capabilities and motivation [7].